GENOWAY: insider trades · France · AMF

About GENOWAY

genOway is a French biotechnology company listed on Euronext Growth Paris under ticker ALGEN and ISIN FR0004053510. Founded in 1999 and headquartered in Lyon, France, the company designs, develops and commercializes genetically modified preclinical models, mainly mice, rats and cell lines, for pharmaceutical companies, biotech groups and academic institutions. Its core mission is to better “mimic” humans and disease biology in order to improve the predictive power of preclinical research and help drug developers identify the most effective and safest candidates earlier in the R&D process. The group relies on a technological platform supported by exclusive worldwide licenses and advanced gene-editing expertise, enabling it to create knockout, knock-in, humanized, conditional and inducible models tailored to specific scientific needs. Historically, genOway built its reputation around customized models, but it has progressively expanded into a proprietary catalog of translational off-the-shelf models. Since 2018, this catalog has been particularly focused on immuno-oncology and immunotherapy, two high-growth areas in modern drug discovery. The company also provides bespoke model-generation services for target validation, drug screening, efficacy studies and non-regulatory safety testing. This hybrid model — combining high-value custom projects with recurring catalog products — is central to genOway’s competitive positioning and long-term growth profile. The company has a meaningful international footprint. genOway employs more than 140 people representing 17 nationalities, serves customers in 28 countries across five continents, and works with 380 academic institutions and 170 life sciences companies, including 17 of the world’s top 20 pharmaceutical companies. Its commercial reach is supported by an international network of affiliates and distributors across North America, Europe and Asia, as well as a reinforced presence in China through a Shanghai joint venture. This geographic diversification strengthens its proximity to major research hubs and supports its international expansion strategy. From a strategic and financial standpoint, genOway has emphasized sustained organic growth, driven by catalog expansion, commercial organization upgrades and the ROUTE50+ strategy, later extended into ROUTE50+DATA. The company has also highlighted improved profitability, with EBITDA margins above its 15% target threshold, and continues to communicate ambitions for double-digit growth. Overall, genOway is a specialized, science-driven and internationally oriented preclinical research company operating at the intersection of biotechnology, gene editing and outsourced services for the pharmaceutical industry.